Therefore, this study aimed to develop and evaluate machine learning (ML) models to predict infliximab and anti-drug antibody (ADA) concentrations in patients with inflammatory bowel disease (IBD) receiving maintenance infliximab therapy.<h4>Methods</h4>A total of 1,806 infliximab and ADA concentration measurements were prospectively collected from 149 IBD patients. The gene discussed is ADA; the disease is inflammatory bowel disease.